3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
37
Neoplasms
30
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Rectal Neoplasms
3
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colonic Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oligodendroglioma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Skin Neoplasms
1
Interventions
Sorafenib
121
Nivolumab
36
pembrolizumab
32
Bevacizumab
28
lenvatinib
27
Doxorubicin
23
Radiosurgery
21
Radiofrequency Ablation
20
Oxaliplatin
20
Hepatectomy
18
Fluorouracil
15
Capecitabine
15
Magnetic Resonance Spectroscopy
14
atezolizumab
13
Leucovorin
13
Cisplatin
13
Gemcitabine
11
Erlotinib Hydrochloride
11
tislelizumab
9
Sirolimus
9
Radiotherapy
9
Irinotecan
9
Ipilimumab
9
cabozantinib
8
Liver Transplantation
8
regorafenib
7
Ramucirumab
7
Folfox protocol
7
Embolization, Therapeutic
7
sintilimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Hepatocellular
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts